Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare name with strong near-term evidence: Q1 2026 raised full-year guidance, Unity Confirm launch, peer-reviewed Northstar Response support, new oncology CMO, Q1 revenue of $108.4M, gross margin near 73%, positive free cash flow, and shares up about 19% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Modest Returns ⢠Equity Funding BLLN has exceptional liquidity and improving margins, but modest returns, equity-funded cash growth, and an extreme valuation make the shares high risk at current levels.
Price Behavior
Key Price Behavior Insights: ⢠Higher-range trend ⢠Resistance rejection ⢠Support watch Support Level: $100â101; stronger $95â97 Resistance Level: $110â111 BLLN remains bullish above $100â101 but is stretched after retreating from $110â111 resistance, with a break below $95â97 signaling reversal risk.
Sentiment & News
Key News Insights: ⢠Test expansion ⢠Investor outreach ⢠Insider disposals BillionToOne expanded its liquid-biopsy offerings and investor outreach, but significant insider selling may weigh on sentiment.
AI Summary
BLLN's 64% revenue growth, 70% gross margin and new oncology offerings signal a credible shift toward scalable profitability, but its extreme valuation requires sustained adoption, reimbursement progress and stronger free-cash-flow conversion; investors should wait for evidence that new products translate into durable, reimbursed revenue before underwriting further upside.
Description
BillionToOne, Inc. is a precision diagnostics company that quantifies DNA at single-molecule resolution to support molecular diagnostic applications. Its platform underlies a non-invasive prenatal screen that evaluates fetal chromosomal and genetic risks from maternal blood and a suite of liquid biopsy tests for tumor mutation profiling and methylation-based monitoring of cancer burden. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 23 | Jul 30 | BLLN | BillionToOne, Inc. | Healthcare name with strong near-term evidence: Q1 2026 raised full-year guidance, Unity Confirm launch, peer-reviewed Northstar Response support, new oncology CMO, Q1 revenue of $108.4M, gross margin near 73%, positive free cash flow, and shares up about 19% over 21 trading days. | Closed | +8.3% |
| Jul 16 | Jul 23 | BLLN | BillionToOne, Inc. | Healthcare momentum/catalyst name: stock up about 28% over 21 trading days, supported by Q1 results and guidance raise, a new prenatal product launch, peer-reviewed clinical study support, improving margins, strong liquidity, and positive free cash flow. | Closed | +0.6% |
| Jul 9 | Jul 16 | BLLN | BillionToOne, Inc. | Strong short-term setup with shares up about 22.8% over 21 trading days, a new 21-day high, and price well above its short-term average. Recent catalysts include Unity Confirm launch, raised full-year 2026 guidance, and peer-reviewed Northstar Response data outperforming standard imaging as an immunotherapy outcome predictor, alongside much-improved Q1 margins and strong liquidity. | Closed | +0.2% |
| Jul 1 | Jul 8 | BLLN | BillionToOne, Inc. | Strong momentum with supportive catalysts: stock rose about 31% over 21 trading days to a fresh closing high on 2026-07-01, while Q1 2026 raised full-year guidance, Unity Confirm launched, Northstar Response received peer-reviewed clinical validation, and liquidity remains strong. | Closed | -1.4% |
| Jun 23 | Jun 30 | BLLN | BillionToOne, Inc. | Positive catalyst stack includes Q1 2026 results and raised full-year guidance on 2026-05-06, the Unity Confirm launch on 2026-05-01, analyst upside commentary, and a 22% 21-day gain with improved margins in the latest quarter. | Closed | +15.1% |
| Jun 11 | Jun 18 | BLLN | BillionToOne, Inc. | Constructive healthcare momentum with recent catalysts: launched Unity Confirm on 2026-05-01, reported Q1 2026 results and raised full-year guidance on 2026-05-06, and has conference participation support. Shares are up about 11% over 21 trading days and remain above the 21-day average. | Closed | +5.5% |
| Nov 25 | Dec 2 | BLLN | BillionToOne, Inc. | BillionToOne (BLLN) is a hot IPO momentum candidate, with an 11% post-IPO rally, strong cash position, improving earnings metrics, and robust technical breakout above moving averages and upper Bollinger Band, although near-term overbought conditions suggest cautious positioning. | Closed | -11.5% |